Thiazolidinediones (TZD), pioglitazone in particular, have been shown to have beneficial effects on liver function and may reduce the risk of NAFLD by enhancing insulin sensitivity and ameliorating liver fat accumulation [9]. This evidence concerns the gene INS and metabolic dysfunction-associated steatotic liver disease.